Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SPRY · Entity 883 | Chief Operating Officer | January 02, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date January 02, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.49 · Expires 2036-01-01 | Direct | 240,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 240,000 · Balance 240,000 F1: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SEELOS THERAPEUTICS, INC.
Report date August 30, 2018 · Filed September 04, 2018
Section 16 reporting ended · disclosed 2018-09-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 115,891 |
Ending reported balance
After 2018-08-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-08-30 · Exercise / conversion · Acquired 81,775 · Balance 159,116 F1: Represents restricted stock units accelerated upon the Reporting Person's involuntary termination. Restricted stock units convert into common stock on a one-for-one basis. Row 2 · 2018-08-30 · Tax withholding · Disposed 43,225 · Balance 115,891 F2: Represents shares forfeited by Reporting Person to cover certain tax liabilities incident to the vesting of the security. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units accelerated upon the Reporting Person's involuntary termination. Restricted stock units convert into common stock on a one-for-one basis.
F2: Represents shares forfeited by Reporting Person to cover certain tax liabilities incident to the vesting of the security.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 5, 2026 21:23 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 240,000 | $0.00 Strike: $11.49 | $0.00 |
DisclosureSEC source: 0001380762-26-000002 · form4-01052026_090119.xml · derivative · entry 1 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2036-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 23:43 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,828 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001380762-25-000005 · form4-11142025_111134.xml · derivative · entry 3 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,828 shares Expires 2028-11-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 23:43 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 21,828 | $8.71 | $190,049.85 |
DisclosureSEC source: 0001380762-25-000005 · form4-11142025_111134.xml · nonDerivative · entry 2 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,789 F2 · price: The weighted average sale price for the transaction report was $8.7067, and the range of prices was between $8.63 and $8.835. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| November 13, 2025 Filed Nov 14, 2025 23:43 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 21,828 | $0.64 | $13,969.92 |
DisclosureSEC source: 0001380762-25-000005 · form4-11142025_111134.xml · nonDerivative · entry 1 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 1,628 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") on December 31, 2024 and 3,137 shares acquired under the ESPP on June 30, 2025. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 21:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 261,900 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0001415889-25-000462 · form4-01032025_040128.xml · derivative · entry 1 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 261,900 Underlying: Common Stock · 261,900 shares Expires 2035-01-01 F1 · derivative.exercise_date: The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025. Read SEC document |
| December 12, 2024 Filed Dec 14, 2024 00:52 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001415889-24-029376 · form4-12142024_121223.xml · derivative · entry 6 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,828 Underlying: Common Stock · 25,000 shares Expires 2028-11-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 12, 2024 Filed Dec 14, 2024 00:52 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 25,000 | $12.30 | $307,432.50 |
DisclosureSEC source: 0001415889-24-029376 · form4-12142024_121223.xml · nonDerivative · entry 4 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,024 F3 · price: The weighted average sale price for the transaction report was $12.2973, and the range of prices were between $12.13 and $12.60. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 12, 2024 Filed Dec 14, 2024 00:52 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 25,000 | $0.64 | $16,000.00 |
DisclosureSEC source: 0001415889-24-029376 · form4-12142024_121223.xml · nonDerivative · entry 3 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2024 Filed Dec 14, 2024 00:52 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001415889-24-029376 · form4-12142024_121223.xml · derivative · entry 5 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,828 Underlying: Common Stock · 15,000 shares Expires 2028-11-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| December 11, 2024 Filed Dec 14, 2024 00:52 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 15,000 | $12.43 | $186,426.00 |
DisclosureSEC source: 0001415889-24-029376 · form4-12142024_121223.xml · nonDerivative · entry 2 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,024 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2023. F2 · price: The weighted average sale price for the transaction report was $12.4284, and the range of prices were between $12.34 and $12.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 11, 2024 Filed Dec 14, 2024 00:52 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 15,000 | $0.64 | $9,600.00 |
DisclosureSEC source: 0001415889-24-029376 · form4-12142024_121223.xml · nonDerivative · entry 1 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 22:51 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001415889-24-021886 · form4-08212024_100842.xml · derivative · entry 3 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,828 Underlying: Common Stock · 50,000 shares Expires 2028-11-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 22:51 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 50,000 | $15.00 | $750,000.00 |
DisclosureSEC source: 0001415889-24-021886 · form4-08212024_100842.xml · nonDerivative · entry 2 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,024 F1 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2023. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 22:51 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 50,000 | $0.64 | $32,000.00 |
DisclosureSEC source: 0001415889-24-021886 · form4-08212024_100842.xml · nonDerivative · entry 1 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.64 | $0.00 |
DisclosureSEC source: 0001415889-24-021364 · form4-08152024_040809.xml · derivative · entry 3 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 111,828 Underlying: Common Stock · 30,000 shares Expires 2028-11-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | SaleCommon Stock | 30,000 | $13.00 | $390,000.00 |
DisclosureSEC source: 0001415889-24-021364 · form4-08152024_040809.xml · nonDerivative · entry 2 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,024 F2 · kind: The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 31, 2023. Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:30 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | Exercise / conversionCommon Stock | 30,000 | $0.64 | $19,200.00 |
DisclosureSEC source: 0001415889-24-021364 · form4-08152024_040809.xml · nonDerivative · entry 1 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,159 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan ("ESPP") on June 30, 2023, 1,013 shares acquired under the ESPP on December 29, 2023 and 2,852 shares acquired under the ESPP on June 29, 2024. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:42 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 350,000 | $0.00 Strike: $5.58 | $0.00 |
DisclosureSEC source: 0001209191-24-000810 · doc4.xml · derivative · entry 1 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:00 UTC | ARS Pharmaceuticals, Inc. SPRY · Entity 883 | GrantStock option (right to buy) · Derivative | 145,000 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001209191-23-001926 · doc4.xml · derivative · entry 1 Dorsey Brian · CIK 0001380762 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2033-01-02 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 17:04 UTC | SEELOS THERAPEUTICS, INC. APRI · Entity 93662 | Tax withholdingCommon Stock | 43,225 | $0.33 | $14,264.25 |
DisclosureSEC source: 0001017491-18-000083 · wf-form4_153609507190879.xml · nonDerivative · entry 2 Dorsey Brian · CIK 0001380762 · Former SVP, Chief Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,891 F2 · shares: Represents shares forfeited by Reporting Person to cover certain tax liabilities incident to the vesting of the security. Read SEC document |
| August 30, 2018 Filed Sep 4, 2018 17:04 UTC | SEELOS THERAPEUTICS, INC. APRI · Entity 93662 | Exercise / conversionCommon Stock | 81,775 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001017491-18-000083 · wf-form4_153609507190879.xml · nonDerivative · entry 1 Dorsey Brian · CIK 0001380762 · Former SVP, Chief Dev Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,116 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents restricted stock units accelerated upon the Reporting Person's involuntary termination. Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Represents restricted stock units accelerated upon the Reporting Person's involuntary termination. Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 03, 2018 Filed Jan 3, 2018 19:45 UTC | SEELOS THERAPEUTICS, INC. APRI · Entity 93662 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $2.11 | $0.00 |
DisclosureSEC source: 0001017491-18-000006 · wf-form4_151502672545044.xml · derivative · entry 2 Dorsey Brian · CIK 0001380762 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-01-03 F2 · derivative.exercise_date: This option shall vest with respect to one-fourth of the underlying shares upon the first anniversary of the grant date, and then with respect to the remaining shares monthly thereafter over the next three years so the option will be fully vested as of 1/3/2022, subject to the Reporting Person's continued employment or service to the Issuer through such date. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 19:45 UTC | SEELOS THERAPEUTICS, INC. APRI · Entity 93662 | Tax withholdingCommon Stock | 5,485 | $1.84 | $10,092.40 |
DisclosureSEC source: 0001017491-18-000006 · wf-form4_151502672545044.xml · nonDerivative · entry 1 Dorsey Brian · CIK 0001380762 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,116 F1 · shares: Represents shares forfeited by Reporting Person to cover certain tax liabilities incident to the vesting of the security. Read SEC document |
| September 05, 2017 Filed Sep 7, 2017 16:09 UTC | SEELOS THERAPEUTICS, INC. APRI · Entity 93662 | Tax withholdingCommon Stock | 14,093 | $1.56 | $21,985.08 |
DisclosureSEC source: 0001017491-17-000101 · wf-form4_150481494394097.xml · nonDerivative · entry 1 Dorsey Brian · CIK 0001380762 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,601 Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 16:10 UTC | SEELOS THERAPEUTICS, INC. APRI · Entity 93662 | GrantCommon Stock | 75,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001017491-17-000087 · wf-form4_149669343893094.xml · nonDerivative · entry 1 Dorsey Brian · CIK 0001380762 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,694 F1 · kind: Award of 75,000 Restricted Stock Units ("RSUs") under the Issuer's Amended and Restated 2012 Stock Long Term Incentive Plan with half of the underlying shares vesting in the first open trading window following the Issuer's submission of Vitaros in the United States to the Food and Drug Administration ("FDA") and the other half of the underlying shares vesting in the first open trading window following the Issuer's receipt of marketing approval of Vitaros in the United States by the FDA, subject to the Reporting Person's continued employment or service to the Issuer through such date and subject to accelerated vesting upon a change in control of the Issuer. F2 · price: Not Applicable. Read SEC document |
| February 15, 2017 Filed Mar 24, 2017 16:13 UTC | SEELOS THERAPEUTICS, INC. APRI · Entity 93662 | Tax withholdingCommon Stock | 1,495 | $2.78 | $4,156.10 |
DisclosureSEC source: 0001017491-17-000037 · wf-form4_149038637892946.xml · nonDerivative · entry 1 Dorsey Brian · CIK 0001380762 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,694 Read SEC document |
| January 05, 2017 Filed Jan 6, 2017 19:31 UTC | SEELOS THERAPEUTICS, INC. APRI · Entity 93662 | GrantCommon Stock | 75,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001017491-17-000017 · wf-form4_148374905227468.xml · nonDerivative · entry 1 Dorsey Brian · CIK 0001380762 · SVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,189 F1 · kind: Award of 75,000 Restricted Stock Units ("RSUs") under the Issuer's 2012 Stock Long Term Incentive Plan with half of the underlying shares vesting in the first open trading window following the Issuer's receipt of marketing approval of Vitaros in the United States by the Food and Drug Administration and the other half of the underlying shares fully vesting on November 30, 2018, subject to the Reporting Person's continued employment or service to the Issuer through such date and subject to accelerated vesting upon a change in control of the Issuer. F2 · price: Not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.